Join Boehringer Ingelheim in acknowledging producers for their judicious use of antibiotics and commitment to the well-being of their animals.
Boehringer Ingelheim (BI) recognized three dairy producers who demonstrated their commitment to the well-being of animals, consumers and the industry with the judicious use of antibiotics in its Producers for Progress recognition program.
Jami Schultze, herd manager of Maple Ridge Dairy in Stratford, Wisconsin, was chosen as the grand prize winner out of more than 100 applicants in the program’s second year. “I’m grateful to be selected as the grand prize winner,” said Schultze. “It’s great to see producers being recognized for their hard work in using antibiotics judiciously. Over the years, there has been increased interest in and demand for transparency from our consumers. And as producers, it’s our job to earn their trust and confidence that we’re doing the best for our animals.”
Partly due to that increased consumer curiosity, Schultze encourages producers to work with their veterinarian and look at their antibiotic protocols to determine where they can adjust and improve. “We treat cows as individuals, and believe that every cow deserves a diagnosis,” she explained. “Our veterinarian regularly reviews our mastitis cases and protocols to make sure we’re up to date and giving the best treatment. When we do treat, we make sure to do it responsibly by using the proper antibiotic, dose and duration.”
The first place winner, Jennifer May, herdsman of Fa-Ba Farms, LLC in Canandaigua, New York, pointed out that her operation defines the judicious use of antibiotics as treating the cows with good judgment and sense. “The animals’ health is our number one priority,” she said. “In addition to veterinarian-supervised procedures and protocols, cow comfort plays a huge part in our preventive management strategy.” When cows do get sick, she noted, utilizing good records and milk cultures has helped to reduce antibiotic use and determine the correct treatment. “Since we started culturing, we’ve been able to cut the number of cows we treat for clinical mastitis in half.”
Rod Hissong, co-owner of Mercer Vu Farms Inc. in Mercersburg, Pennsylvania, is the second place winner. Hissong centers the farm’s herd management program around preventing problems before they happen, keeping animal welfare and care top of mind. “Our philosophy is that there’s a time and a place for antibiotics on our operation,” he asserted. When our cows do get sick and need treatment, we want to make sure we’re using the right antibiotic for the bacteria present. Preventing disease and only using antibiotics when necessary not only keeps tools in our toolbox, but is right for the animal and the consumer.”
BI’s Producers for Progress recognition program celebrates those who help protect the future of the industry. “We’re proud to salute those producers who have implemented these proactive practices, especially in these trying times,” said Dr. Linda Tikofsky, senior associate director, dairy professional veterinary services for BI. “Antibiotics are important to the well-being of cattle, but we have a responsibility to use them at the right time, at the proper dosage, for the appropriate length of time, and with veterinary oversight.”
Producers for Progress is targeted to customers of BI mastitis treatment products. Applicants were asked to answer questions about their preventive management practices, their views on the judicious use of antibiotics, and to describe their mastitis treatment protocols. Applicant names and operations were anonymous and judging was based on the following selection criteria:
- Demonstrated understanding of and passion for the judicious use of antibiotics
- Commitment to animal well-being
Judges for this year’s program included Dr. Sandra Godden, DVM, University of Minnesota; Dr. Patrick Gorden, DVM, Iowa State University; and Dr. Linda Tikofsky, DVM, BI.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 percent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal well-being through our large portfolio of advanced, preventive healthcare products and services. With net sales of €3.9 billion and around 10,000 employees worldwide, we are present in more than 150 markets. For more information click here.